BioNTech SE ADR (BNTX) News

BioNTech SE ADR (BNTX): $91.34

1.13 (-1.22%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

Add BNTX to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#71 of 360

in industry

Filter BNTX News Items

BNTX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

BNTX News Highlights

  • For BNTX, its 30 day story count is now at 13.
  • Over the past 23 days, the trend for BNTX's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • The most mentioned tickers in articles about BNTX are MRNA, SE and CVAC.

Latest BNTX News From Around the Web

Below are the latest news stories about BIONTECH SE that investors may wish to consider to help them evaluate BNTX as an investment opportunity.

This Vaccine Maker’s Stock Is Worth Owning

The vaccine maker has so much cash that it would have appealed to Warren Buffett’s mentor, famed value manager Benjamin Graham.

Yahoo | December 28, 2023

15 Undervalued Defensive Stocks For 2024

In this article, we discuss the 15 undervalued defensive stocks for 2024. To skip the detailed overview of the market and defensive stocks, go directly to the 5 Undervalued Defensive Stocks For 2024. Defensive stocks are shares of companies that remain relatively stable during economic downturns as opposed to cyclical stocks. Defensive stocks usually outperform […]

Yahoo | December 24, 2023

BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Endometrial Cancer

Designation is based on Phase 1/2 safety and efficacy data in patients with Human Epidermal Growth Factor Receptor 2 (“HER2”)-expressing advanced endometrial cancer with encouraging early signs of anti-tumor activityBreakthrough Therapy designation will allow for an expedited development and regulatory review of BNT323/DB-1303Endometrial or uterine cancer is the second most common gynecologic cancer globally with over 400,000 cases occurring each year MAINZ, Germany and SHANGHAI, China, December

Yahoo | December 21, 2023

Why Is COVID-19 Vaccine Player CureVac Stock Plummeting Today?

A German court has invalidated a patent central to CureVac N.V's (NASDAQ: CVAC) lawsuit against BioNTech SE (NASDAQ: BNTX) related to seeking fair compensation for infringement of a portfolio of CureVac's intellectual property rights utilized in Comirnaty, BioNTech, and Pfizer Inc's (NYSE: PFE) mRNA COVID-19 vaccine. The ruling represents the first decision on validity in ongoing patent litigation between CureVac and BioNTech in Germany, involving eight CureVac intellectual property rights. Proc

Yahoo | December 19, 2023

UPDATE 2-German court quashes CureVac patent after challenge by BioNTech

A German court on Tuesday invalidated a patent that was the basis of a patent violation lawsuit brought by CureVac against its domestic rival BioNTech, in a blow to CureVac's claims for a share in billions of euros in COVID-19 vaccine revenues. CureVac's Nasdaq-listed shares plunged 35% to a record low after the verdict.

Yahoo | December 19, 2023

BioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda

Set-up of first BioNTainer as high-tech manufacturing solution for mRNA medicines is a critical step in establishing a resilient vaccine ecosystem in Africa and future pandemic preparednessBioNTech plans to complete all buildings at the Kigali site and start local training of specialized personnel in the facility in 2024, with test mRNA production for process validation to be initiated in 2025Upon successful validation, the Kigali facility will serve as a lighthouse project for subsequent mRNA-b

Yahoo | December 18, 2023

BioNTech aims to start mRNA vaccine output in Rwanda in 2025

COVID-19 vaccine maker BioNTech aims to start production at its mRNA vaccine factory site in Rwanda in 2025, company officials said on Monday, the first foreign company mRNA vaccine manufacturing site on the continent. “Africa will have one of the most advanced manufacturing facilities in the world," Ugur Sahin, BioNTech co-founder and chief executive officer, said. "These BioNTainers will able to manufacture any kind of mRNA vaccines.”

Yahoo | December 18, 2023

3 Stocks Down 30% or More This Year That Wall Street Expects to Skyrocket in 2024

Analysts think these beaten-down stocks could rebound strongly in the new year.

Yahoo | December 18, 2023

Barron’s 10 Favorite Stocks for 2024

Barron’s annual list of unloved stocks ranges from tech giant Alibaba to miner Barrick to auto rental stalwart Hertz Global.

Yahoo | December 15, 2023

30 Largest Pharmaceutical Companies in the World

In this article, we will be taking a look at the 30 largest pharmaceutical companies in the world. To skip our detailed analysis, you can go directly to see the 10 Largest Pharmaceutical Companies in the World. The world’s leading pharmaceutical companies became the center of attention for people all over the world as a […]

Yahoo | December 12, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!